FDA and Industry GDUFA II Implementation Quarterly Meetings – 2Q2017 Meeting
June 29, 2017, 10:00 AM – 12:00 PM
FDA White Oak Campus, Silver Spring, MD
Building 32, Room 1333

Agenda

- Drug Master File (DMF) review and Complete Response Letter deficiencies
- DMF related Generic Drug User Fee Amendments II (GDUFA II) enhancements
- Pre-Submission Facility Correspondence
- Office of Regulatory Affairs reorganization

Participants

FDA:		Industry:	
Donald Ashley	CDER	Deborah Autor	AAM (Mylan)
Carter Beach	CDER	John DiLoreto	BPTF
Amy Bertha	CDER	David Gaugh	AAM
Michael Kopcha	CDER	Mark Hendrickson	AAM
Richard Moscicki	CDER	Kiran Krishnan	AAM (Apotex)
Ann Marie Montemurro	ORA	Claudia Martins	EFCG (Hovione)
David Skanchy	CDER (DMF advisor)	Matthew Moran	EFCG (BioPharmChem)
Kathleen Uhl	CDER	Alan Nicholls	BPTF (Copperhead)
		Ariadna Olle	EFCG (Medichem)
		Laura Parks	PBOA (Patheon)
		Lisa Parks	AAM
		Gil Roth	PBOA
		Andrew Sweet	BPTF (PCI Synthesis)
		Scott Tomsky	AAM (Teva)

Drug Master File Reviews and Deficiencies

Industry stated that they have seen an increase in the number of DMF deficiencies since GDUFA I started. Industry feels this increase has "raised the bar" and some deficiencies are inappropriate. Some examples industry provided include, in their opinion, improper application of drug product regulations to active pharmaceutical ingredient (API) manufacturers, and excessive information requests for raw material information and in process controls. Industry requested that in order to work out these issues, teleconferences and email correspondences would be helpful to better understand the deficiencies and context and to work out potential alternate scientific approaches, if appropriate.

FDA thanked industry for bringing these issues to their attention. FDA agreed that dialogue is helpful to work out issues. Under GDUFA I industry has the ability to request teleconferences with FDA to discuss first cycle complete response letter (CRL) deficiencies. A statement is included in FDA's CRL which provides industry with the name of a FDA project manager to contact in order to request a teleconference.

FDA has seen a very low response rate on teleconference requests. Only 2-3% of CRLs generate a request for a teleconference. Under GDUFA I, industry has 10 U.S. business days to request a teleconference. In order to give industry more time, GDUFA II expands this time to 20 days. Under GDUFA II industry will also have the option to email questions, as well as have a follow

up email exchange, along with a teleconference. FDA and industry agree that it is important to make sure the mechanisms for communication are understood and utilized.

DMF Enhancements in GDUFA II

The DMF performance goal in GDUFA II is to complete the initial completeness assessment review for 90 percent of Type II API DMFs within 60 days of the later of the date of DMF submission or DMF fee payment. In preparation for GDUFA II, FDA has been tracking our performance since January 2017 against this metric and the numbers are: 169 out of 186 completed within 60 days (91%). The completeness assessment process was moved into the Panorama IT system in January 2017 which will improve tracking capability. The following bullet points outline the GDUFA II DMF enhancements:

- Communication of DMF Review Comments - FDA will ensure that DMF review comments submitted to the DMF holder are issued at least in parallel with the issuance of review comments relating to the DMF for the Abbreviated New Drug Application (ANDA). This commitment applies to comments to the applicant issued in any ANDA CRL and comments issued in the first IR letter by the drug product review discipline. DMFs were fully migrated into Panorama IT system in November 2016 which allows DMF reviews to be managed and tracked like all other review disciplines.

- Teleconferences to Clarify DMF First Cycle Review Deficiencies - Teleconferences will be implemented as they are now under GDUFA I with the following minor changes: a firm has 20 U.S. business days to submit the request and FDA will strive to grant a teleconference within 30 (calendar) days. A new option will be added providing for clarification requests to also be made via email.

- DMF First Adequate Letters – This is a new communication to let the DMF holder know in "real time" (i.e. issued at the time of DMF review completion) when their DMF becomes adequate for the first time. FDA has created a letter template, the process and IT requirements are currently being designed. FDA hopes this letter will help communication between the DMF holder and the applicant and prevent late-cycle unsolicited amendments to the DMF that are disruptive to the ANDA approval process.

- DMF No Further Comment (NFC) Letters – These letters will proceed as they do now under GDUFA I. This process was migrated into the Panorama IT system in February 2017. Under GDUFA II the default communication method for the NFC letter will be email. The difference between a First Adequate Letter and a NFC letter is primarily a matter of timing. The NFC letter is issued upon approval/tentative approval action on the referencing ANDA which may occur much later than the actual review that determined the DMF is adequate.

- Guidance on Post-Approval Changes to Type II API DMFs – This guidance development effort is on track to meet the October 1, 2018 issuance date.

Pre-Submission Facility Correspondence (PFC)
A draft guidance for industry on the PFC published in June 2017. FDA and industry discussed the appropriate mechanism for sharing feedback and providing comments which is to submit comments to the Docket. FDA will carefully review and consider all comments before finalizing the guidance. FDA's Good Guidance Practices (21 CFR 10.115) outlines the guidance development process, including how interested parties can participate in the process.

Office of Regulatory Affairs Reorganization
Industry asked FDA if there were any changes to the facilities information, specifically the information regarding the Office of Regulatory Affairs reorganization (also known as the program alignment initiative), provided at the March 2017 quarterly meeting. FDA responded there were no additional updates at this point.

Post- Meeting Note

- FDA's Regulatory Education for Industry Generic Drug Forum held in April 2017 was recorded. and is a good source of educational material regarding the generics program and GDUFA II. (Link to recording: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/ucm540969.htm).

- CDER's guidance agenda is a good resource for information on future areas of guidance development. The 2017 guidance agenda published in April 2017, and it is updated annually. Guidances related to GDUFA II implementation were on the April 2017 agenda. Future guidances related to GDUFA II implementation will be listed on future guidance agendas. (CDER Guidance Agenda: https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm417290.pdf).